Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>BRAF</i> V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis

14 Jun 2016

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V600E mutation in 36/97 (37.1%) retrospectively enrolled patients with LCH; concordant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histiocytic Disorders and Treatments
Share to Immunotherapy and Immune Responses
Share to Vascular Malformations and Hemangiomas

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27622040
DOI: 10.1080/2162402x.2016.1185582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>BRAF</i> V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosisPMID 27622040Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.Semantic proximity Read ↗

BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcomeSemantic proximity Read ↗

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.Semantic proximity Read ↗

BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.Semantic proximity Read ↗

Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.Semantic proximity Read ↗

Recent advances in the understanding of Langerhans cell histiocytosisSemantic proximity Read ↗

Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.Semantic proximity Read ↗

Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.Semantic proximity Read ↗

Langerhans cell histiocytosis: current advances in molecular pathogenesis.Semantic proximity Read ↗

Blood spotlight on Langerhans cell histiocytosisSemantic proximity Read ↗

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.